China’s BeiGene raises $175m from follow-on

Nasdaq-listed Chinese biopharmaceutical firm BeiGene has bagged $175m from a follow-on public offering of American Depositary Shares (ADSs).

  • By Jonathan Breen
  • 11 Aug 2017

The company announced the deal — its second follow-on in less than a year — on Wednesday evening, with an original plan to sell $125m worth of ADSs.

But it boosted the size of the trade to $175m, and on Thursday priced 2.5m ADSs, each equal to ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Panda Bonds Top Arrangers

Rank Arranger Share % by Volume
1 Bank of China (BOC) 28.62
2 CITIC Securities 21.06
3 China CITIC Bank Corp 9.72
4 China Merchants Bank Co 9.18
5 Industrial and Commercial Bank of China (ICBC) 7.56

Bookrunners of Asia-Pac (ex-Japan) ECM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 CITIC Securities 16,270.37 85 6.32%
2 UBS 14,128.60 88 5.49%
3 Goldman Sachs 11,744.37 58 4.56%
4 China International Capital Corp Ltd 11,422.00 55 4.44%
5 Morgan Stanley 10,900.56 58 4.23%

Bookrunners of Asia Pacific (ex-Japan) G3 DCM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 HSBC 35,178.30 245 8.08%
2 Citi 34,267.00 196 7.87%
3 JPMorgan 26,001.66 142 5.97%
4 Bank of America Merrill Lynch 21,496.54 111 4.93%
5 Standard Chartered Bank 19,923.39 139 4.57%

Asian polls & awards